Psycho-oncology · 2026
Fear of Progression in Pediatric Cancer Patients and Their Parents: Trajectories, Prevalence, and Correlates Across Acute Treatment and Follow-Up Care.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Herrmann Jessy, Herzog Kristina, Martini Julia, Santel Anja, Kulisch Leonard Konstantin, Kühl Jörn-Sven, Schepper Florian
Аннотация
PURPOSE: Fear of progression (FoP) represents a significant psychological burden for pediatric cancer patients and their parents. This study investigates FoP levels across acute treatment (AcT) and follow-up care (FuC) and examines trajectories over time, associated sociodemographic factors, and parent-child associations. It also proposes clinically relevant thresholds for psychosocial care.
METHODS: A total of 171 patient-parent dyads participated in a cross-sectional and longitudinal study. Children aged 7-18 and one parent per child completed the Fear of Progression Questionnaire-Short Form (FoP-Q-SF). Data were collected during AcT (two time points) and FuC. Statistical analyses included nonparametric tests and correlation analyses.
RESULTS: FoP levels were significantly lower during FuC compared to AcT for both children and parents, and parental FoP decreased over the 1-year follow-up period. Parents consistently showed higher FoP than their children, and a significant parent-child correlation emerged in FuC. FoP was higher in girls and was positively associated with child age and negatively associated with parent age. Using suggested thresholds, 57.8% of parents showed dysfunctional FoP. Among children, 45.2% reported low, 40% moderate, and 14.8% high FoP.
CONCLUSION: Although levels of FoP are lower in FuC than in AcT, they remain a prevalent burden-particularly for younger parents, older children, and girls. The observed parent-child associations highlight the need for family-oriented psychosocial care. A proposed three-stage cut-off (low, moderate, high FoP) may guide clinical decision-making and support tailored treatment strategies. Routine screening and preventive approaches are recommended to mitigate FoP and its potential intergenerational transmission.
TRIAL REGISTRATION: The study has been pre-registered at the German Clinical Trials Register (DRKS 00022034, registered 29th of June 2020) and at the Open Science Foundation (https://osf.io/fuahc).
METHODS: A total of 171 patient-parent dyads participated in a cross-sectional and longitudinal study. Children aged 7-18 and one parent per child completed the Fear of Progression Questionnaire-Short Form (FoP-Q-SF). Data were collected during AcT (two time points) and FuC. Statistical analyses included nonparametric tests and correlation analyses.
RESULTS: FoP levels were significantly lower during FuC compared to AcT for both children and parents, and parental FoP decreased over the 1-year follow-up period. Parents consistently showed higher FoP than their children, and a significant parent-child correlation emerged in FuC. FoP was higher in girls and was positively associated with child age and negatively associated with parent age. Using suggested thresholds, 57.8% of parents showed dysfunctional FoP. Among children, 45.2% reported low, 40% moderate, and 14.8% high FoP.
CONCLUSION: Although levels of FoP are lower in FuC than in AcT, they remain a prevalent burden-particularly for younger parents, older children, and girls. The observed parent-child associations highlight the need for family-oriented psychosocial care. A proposed three-stage cut-off (low, moderate, high FoP) may guide clinical decision-making and support tailored treatment strategies. Routine screening and preventive approaches are recommended to mitigate FoP and its potential intergenerational transmission.
TRIAL REGISTRATION: The study has been pre-registered at the German Clinical Trials Register (DRKS 00022034, registered 29th of June 2020) and at the Open Science Foundation (https://osf.io/fuahc).